{"id":25699,"date":"2022-07-04T10:50:05","date_gmt":"2022-07-04T09:50:05","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=25699"},"modified":"2022-07-04T10:50:07","modified_gmt":"2022-07-04T09:50:07","slug":"report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/","title":{"rendered":"Report by the by the Access to Medicine Foundation: Pharma falls short on LMIC antibiotics"},"content":{"rendered":"\n<p>Article published on June 15, 2022 on <a href=\"https:\/\/linksbridge.com\/news\/23884?utm_medium=email&amp;_hsmi=218148525&amp;_hsenc=p2ANqtz-9ZJtkoCToTXarSjSEmCzZ5kovBTCFoF9DHNbCVUFVutAX7C9CCN8E0I7I1AoW03vTDnyn5q7rwTc5cPOGVwkeDACvuUA&amp;utm_content=218148525&amp;utm_source=hs_email\" target=\"_blank\" rel=\"noreferrer noopener\">Linksbridge.com<\/a><\/p>\n\n\n\n<p>Pharma companies are overlooking opportunities to expand access to antibiotics in resource-limited settings, \u201cresulting in significant gaps,\u201d according to\u00a0<a href=\"https:\/\/accesstomedicinefoundation.org\/publications\/lack-of-access-to-medicine-is-a-major-driver-of-drug-resistance-how-can-pharma-take-action-1\" target=\"_blank\" rel=\"noreferrer noopener\">a report<\/a>\u00a0published last week by the Access to Medicine Foundation.<\/p>\n\n\n\n<p>The document outlines 13 strategies for improving access, ranging from the \u201cvital first step\u201d of registering drugs in LMICs to technology transfers, product donations and more. A series of six case studies highlights tangible access initiatives from companies including Pfizer, Sanofi and Shionogi.&nbsp;<\/p>\n\n\n\n<p>The report also references market-nurturing incentives like the U.K.\u2019s subscription purchase model. <\/p>\n\n\n\n<p>On Wednesday, Britain\u2019s National Health Service\u00a0<a href=\"https:\/\/www.england.nhs.uk\/2022\/06\/nhs-lands-breakthrough-in-global-battle-against-superbugs\/\" target=\"_blank\" rel=\"noreferrer noopener\">announced<\/a>\u00a0the rollout of the first drugs under that plan: Pfizer\u2019s ceftazidime-avibactam and Shionogi\u2019s cefiderocol\u00a0(Fetroja).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Article published on June 15, 2022 on Linksbridge.com Pharma companies are overlooking opportunities to expand access to antibiotics in resource-limited settings, \u201cresulting in significant gaps,\u201d according to\u00a0a report\u00a0published last week by the Access to Medicine Foundation. The document outlines 13 strategies for improving access, ranging from the \u201cvital first step\u201d of registering drugs in LMICs [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":25705,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[37],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Report by the by the Access to Medicine Foundation: Pharma falls short on LMIC antibiotics - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Report by the by the Access to Medicine Foundation: Pharma falls short on LMIC antibiotics - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-04T09:50:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-04T09:50:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pauvrete.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"913\" \/>\n\t<meta property=\"og:image:height\" content=\"548\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Report by the by the Access to Medicine Foundation: Pharma falls short on LMIC antibiotics\",\"datePublished\":\"2022-07-04T09:50:05+00:00\",\"dateModified\":\"2022-07-04T09:50:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/\"},\"wordCount\":134,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pauvrete.jpg\",\"articleSection\":[\"Bilans, rapports et recommandations\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/\",\"name\":\"Report by the by the Access to Medicine Foundation: Pharma falls short on LMIC antibiotics - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pauvrete.jpg\",\"datePublished\":\"2022-07-04T09:50:05+00:00\",\"dateModified\":\"2022-07-04T09:50:07+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pauvrete.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pauvrete.jpg\",\"width\":913,\"height\":548,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Bilans, rapports et recommandations\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Report by the by the Access to Medicine Foundation: Pharma falls short on LMIC antibiotics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Report by the by the Access to Medicine Foundation: Pharma falls short on LMIC antibiotics - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/","og_locale":"fr_FR","og_type":"article","og_title":"Report by the by the Access to Medicine Foundation: Pharma falls short on LMIC antibiotics - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2022-07-04T09:50:05+00:00","article_modified_time":"2022-07-04T09:50:07+00:00","og_image":[{"width":913,"height":548,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pauvrete.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Report by the by the Access to Medicine Foundation: Pharma falls short on LMIC antibiotics","datePublished":"2022-07-04T09:50:05+00:00","dateModified":"2022-07-04T09:50:07+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/"},"wordCount":134,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pauvrete.jpg","articleSection":["Bilans, rapports et recommandations"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/","name":"Report by the by the Access to Medicine Foundation: Pharma falls short on LMIC antibiotics - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pauvrete.jpg","datePublished":"2022-07-04T09:50:05+00:00","dateModified":"2022-07-04T09:50:07+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pauvrete.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pauvrete.jpg","width":913,"height":548,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/report-by-the-by-the-access-to-medicine-foundation-pharma-falls-short-on-lmic-antibiotics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Bilans, rapports et recommandations","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/"},{"@type":"ListItem","position":4,"name":"Report by the by the Access to Medicine Foundation: Pharma falls short on LMIC antibiotics"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-25 02:48:48","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/25699"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=25699"}],"version-history":[{"count":4,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/25699\/revisions"}],"predecessor-version":[{"id":25711,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/25699\/revisions\/25711"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/25705"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=25699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=25699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=25699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}